Peer-influenced content. Sources you trust. No registration required. This is HCN.

MedPage TodayASCO Addresses PARP Controversy in Guideline Update

A response to “practice-changing data” in the first- and second-line setting

The American Society of Clinical Oncology (ASCO) has amended its advice against routinely administering PARP inhibitor monotherapy to patients with recurrent platinum-sensitive epithelial ovarian cancer in the second or later-line situation.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form